![Surface expression of CD19, CD20, CD22, and CD37 in multiple subtypes... | Download Scientific Diagram Surface expression of CD19, CD20, CD22, and CD37 in multiple subtypes... | Download Scientific Diagram](https://www.researchgate.net/publication/332385293/figure/fig1/AS:747042058039298@1555120114748/Surface-expression-of-CD19-CD20-CD22-and-CD37-in-multiple-subtypes-of-B-NHL-Flow.png)
Surface expression of CD19, CD20, CD22, and CD37 in multiple subtypes... | Download Scientific Diagram
![Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology](https://journals.asm.org/cms/10.1128/MCB.20.15.5363-5369.2000/asset/49c3a785-d193-466c-ae13-3927c6b6b839/assets/graphic/mb1500155001.jpeg)
Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology
![Cancers | Free Full-Text | Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma Cancers | Free Full-Text | Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma](https://pub.mdpi-res.com/cancers/cancers-13-00981/article_deploy/html/images/cancers-13-00981-g001.png?1614675807)
Cancers | Free Full-Text | Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
![Driving Out Chronic Lymphocytic Leukemia With CAR T Cells - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy Driving Out Chronic Lymphocytic Leukemia With CAR T Cells - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy](https://www.astctjournal.org/cms/attachment/15b349eb-1090-4255-ae62-34531ff0131b/gr1_lrg.jpg)
Driving Out Chronic Lymphocytic Leukemia With CAR T Cells - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
![IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies](https://www.mdpi.com/ijms/ijms-21-09531/article_deploy/html/images/ijms-21-09531-g002.png)
IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
![CD37 and CD44 evaluation by flow cytometry: can these markers improve B cell lymphoma characterization? | SpringerLink CD37 and CD44 evaluation by flow cytometry: can these markers improve B cell lymphoma characterization? | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12308-021-00454-8/MediaObjects/12308_2021_454_Fig1_HTML.png)
CD37 and CD44 evaluation by flow cytometry: can these markers improve B cell lymphoma characterization? | SpringerLink
![CD37-Targeted antibody therapeutics. Several anti-CD37 therapies under... | Download Scientific Diagram CD37-Targeted antibody therapeutics. Several anti-CD37 therapies under... | Download Scientific Diagram](https://www.researchgate.net/publication/274728449/figure/fig1/AS:272091136131133@1441882990723/CD37-Targeted-antibody-therapeutics-Several-anti-CD37-therapies-under-clinical.png)
CD37-Targeted antibody therapeutics. Several anti-CD37 therapies under... | Download Scientific Diagram
![IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies](https://www.mdpi.com/ijms/ijms-21-09531/article_deploy/html/images/ijms-21-09531-g001.png)
IJMS | Free Full-Text | CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies
![Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas - ScienceDirect Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S000649712060708X-fx1ab.jpg)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas - ScienceDirect
![Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology](https://journals.asm.org/cms/10.1128/MCB.20.15.5363-5369.2000/asset/7fc6d409-ceaf-4304-85a9-42155b0173d6/assets/graphic/mb1500155004.jpeg)
Targeted Inactivation of the Tetraspanin CD37 Impairs T-Cell-Dependent B-Cell Response under Suboptimal Costimulatory Conditions | Molecular and Cellular Biology
CD37 Antibody, anti-human, REAfinity™ | Recombinant antibodies | MACS Antibodies | Products and services | Hong Kong
![CD37 Mouse anti-Human, Clone: IPO-24, Invitrogen™ 500 μL; Unconjugated Primary Antibodies CD36 to CD40 | Fisher Scientific CD37 Mouse anti-Human, Clone: IPO-24, Invitrogen™ 500 μL; Unconjugated Primary Antibodies CD36 to CD40 | Fisher Scientific](https://assets.fishersci.com/TFS-Assets/LSG/figures/MA5-13567_FACS_PBMC.jpg-650.jpg)
CD37 Mouse anti-Human, Clone: IPO-24, Invitrogen™ 500 μL; Unconjugated Primary Antibodies CD36 to CD40 | Fisher Scientific
![DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies | Blood Cancer Journal DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies | Blood Cancer Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41408-020-0292-7/MediaObjects/41408_2020_292_Fig7_HTML.png)
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies | Blood Cancer Journal
![Phenotypical characterization of the Cd37-/-B cell lymphomas. (A) Flow... | Download Scientific Diagram Phenotypical characterization of the Cd37-/-B cell lymphomas. (A) Flow... | Download Scientific Diagram](https://www.researchgate.net/publication/291172565/figure/fig5/AS:639521288900620@1529485165825/Phenotypical-characterization-of-the-Cd37--B-cell-lymphomas-A-Flow-cytometry-analyses.png)